Chief Physician at Qinghai University Affiliated Hospital, China.
Jiuda Zhao is a Professor and Chief Physician at the Breast Disease Diagnosis and Treatment Center of the Affiliated Hospital of Qinghai University. With over 20 years of experience, he specializes in the diagnosis and treatment of breast cancer. He has been recognized as a high-end innovative talent and has contributed extensively to the field of oncology, focusing on advancing treatment methods for breast cancer.
Profile
Scopus
Education
Jiuda Zhao completed his medical education and specialized training in oncology, focusing on breast cancer treatment. His academic journey is further complemented by his supervisory role, where he mentors doctoral students, contributing to the next generation of medical professionals in oncology.
Experience
Jiuda Zhao has over two decades of clinical experience, particularly in the treatment of breast cancer. His work emphasizes diagnosis, innovative therapies such as immunotherapy and targeted treatments, and he is actively involved in multi-disciplinary approaches (MDT) for breast cancer care. He also contributes to the academic community by serving in various national oncology committees.
Research Interests
Jiuda Zhao’s research is centered on the diagnosis and treatment of breast cancer, especially in high-altitude regions. His focus extends to endocrine therapy, targeted therapy, and immunotherapy, aiming to enhance treatment outcomes for patients. He is also involved in cross-disciplinary areas such as oncology cardiology and oncology genetics, promoting comprehensive cancer care.
Awards
Jiuda Zhao has been honored multiple times for his contributions to oncology, including the prestigious Qinghai Provincial Science and Technology Progress Award in 2022. His commitment to cancer prevention and treatment has also earned him recognition as a high-level talent in Qinghai Province.
Publications
1. Effect of Adding Electroacupuncture to Standard Triple Antiemetic Therapy on Chemotherapy-Induced Nausea and Vomiting: A Randomized Controlled Clinical Trial
- Journal: Journal of Clinical Oncology
- Published: September 6, 2024
- DOI: 10.1200/JCO.24.00099
- Authors: Shen G, Ren D, Zhao F, Wang M, Liu Z, Feng X, He Y, Liu X, Ling X, Zhao Y, Song F, Ma J, Li E, She T, Liu Z, Li Z, Huang S, Chen Y, Yang J, Li X, Duan L, Da M, Zheng Y, Li Y, Zhao J
- Summary: This paper investigates the effectiveness of electroacupuncture in reducing chemotherapy-induced nausea and vomiting when added to the standard triple antiemetic therapy. The study is a randomized controlled trial, offering new insights into improving quality of life for chemotherapy patients.
2. Anlotinib: A Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development
- Journal: Journal of Hematology & Oncology
- Published: September 19, 2018
- DOI: 10.1186/s13045-018-0664-7
- Authors: Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J
- Cited by: 462
- Summary: This paper focuses on Anlotinib, a novel multi-targeting tyrosine kinase inhibitor used in cancer treatment. The research explores its efficacy in various cancer types, emphasizing its clinical potential as a therapeutic agent.
3. Incidence of Antibody-Drug Conjugates-Related Pneumonitis in Patients with Solid Tumors: A Systematic Review and Meta-Analysis
- Journal: Critical Reviews in Oncology/Hematology
- Published: April 2023
- DOI: 10.1016/j.critrevonc.2023.103960
- Authors: Zhu Z, Shen G, Li J, Qiu T, Fang Q, Zheng Y, Xin Y, Liu Z, Zhao F, Ren D, Zhao J
- Summary: This meta-analysis assesses the incidence of pneumonitis caused by antibody-drug conjugates in solid tumor treatments. The study offers critical data for managing this rare but serious side effect in cancer therapy.
4. The Emerging Role of Hypoxia-Inducible Factor-2 Involved in Chemo/Radioresistance in Solid Tumors
- Journal: Cancer Treatment Reviews
- Published: July 2015
- DOI: 10.1016/j.ctrv.2015.05.004
- Authors: Zhao J, Du F, Luo Y, Shen G, Zheng F, Xu B
- Summary: This paper discusses the role of Hypoxia-Inducible Factor-2 (HIF-2) in contributing to chemotherapy and radiotherapy resistance in solid tumors. It highlights new strategies for overcoming treatment resistance.
5. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis
Conclusion
Jiuda Zhao is a highly deserving candidate for the Best Researcher Award. His significant contributions to breast cancer research, particularly in underserved high-altitude regions, demonstrate his expertise, leadership, and dedication to advancing medical science. His innovations, academic influence, and research outputs place him in a strong position for the award. Addressing areas like industry collaboration and international partnerships could further elevate his profile on a global scale.